Physician profile
Bryce Thomas Howe
NPI 1275162224
$1,483.28
in general payments reported to CMS, 2019-2025
17 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.99 · 2022: $99.99 · 2023: $288 · 2024: $652 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $309.10 | 2023-2024 | Xarelto |
| Inari Medical, INC. | $166.80 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $161.71 | 2023-2025 | Zerbaxa, Recarbrio, Dificid |
| Scpharmaceuticals INC. | $143.28 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.28 | 2023-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $99.99 | 2021 | |
| Biogen, INC. | $99.99 | 2022 | |
| Alexion Pharmaceuticals, INC. | $97.09 | 2024-2025 | Ultomiris |
| Melinta Therapeutics, LLC | $76.49 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
| Amgen INC. | $37.90 | 2024 | |
| Janssen Scientific Affairs, LLC | $35.56 | 2023 | Xarelto |
| Boston Scientific Corporation | $32.76 | 2023 | Watchman Access System |
| Stryker Corporation | $29.57 | 2025 | Flowtriever |
| Insmed, INC. | $24.65 | 2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.96 | 2023 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $16.04 | 2025 | Veklury |
| Astrazeneca Pharmaceuticals LP | $15.11 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Howe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.